FLUZONE Quadrivalent - Sanofi Pasteur
Sanofi Pasteur Section 1.3.1 Product Monograph 450/477 - FLUZONE ® Quadrivalent Page 5 of 35 Although the current influenza vaccine can contain one or more of the antigens administered in
Download FLUZONE Quadrivalent - Sanofi Pasteur
Information
Domain:
Source:
Link to this page:
Documents from same domain
PRODUCT MONOGRAPH - Sanofi Pasteur
www.sanofipasteur.caSanofi Pasteur Section 1.3.1 Product Monograph 450 - FLUZONE® Quadrivalent Page 2 of 35 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .....5
Related documents
Product Monograph - RA 0004399 - …
www.cliniciansoftheworld.orgsanofi pasteur 331 – DUKORAL® Product Monograph . PRODUCT MONOGRAPH . DUKORAL ® Oral, Inactivated Travellers’ Diarrhea and Cholera Vaccine . Oral Suspension . Active Immunizing Agent for the Prevention of Travellers’ Diarrhea Caused
CO-CODAMOL 30MG/500MG TABLETS PL …
www.mhra.gov.ukMHRA-UKPAR – Co-codamol 30mg/500mg Tablets PL 17907/0235 -2 - CO-CODAMOL 30MG/500MG TABLETS PL 17907/0235 LAY SUMMARY The Medicines and Healthcare products Regulatory Agency granted Bristol Laboratories
AMISULPRIDE 50 MG, 100 MG AND 200MG …
www.mhra.gov.ukPAR Amisulpride 50 mg, 100 mg & 200 mg tabs, & Amisulpride 400 mg film-coated tabs PL 39891/0004-7 2 AMISULPRIDE 50MG, 100MG AND 200MG TABLETS
GUIDELINES FOR THE MONITORING OF …
www.neneccg.nhs.ukGUIDELINES FOR THE MONITORING OF ANTIMANIC AND PROPHYLACTIC MEDICATION IN BIPOLAR DISORDER NHT Policy number MM-G-023 Date approved by Medicines Management
SUMMARY OF PRODUCT CHARACTERISTICS - Sanofi
www.sanofi-aventis.co.ukSUMMARY OF PRODUCT CHARACTERISTICS 1. Name of the medicinal product Epilim 100mg Crushable Tablets Epilim 200 Enteric …
SUMMARY OF PRODUCT CHARACTERISTICS 1 …
www.sanofi-aventis.co.ukSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Targocid 200mg Teicoplanin 200mg Powder for Injection Targocid 400mg Teicoplanin 400mg Powder for ...
Summary of Stability Data for Licensed Vaccines
path.azureedge.netYes/No is based on published information on whether the vaccine is damaged by freezing. DNF (do not freeze) indicates that the summary of product characteristics (SPC) specifies that the vaccine should not be frozen, and it is assumed, therefore, that the vaccine might be